Compare Gilead Sciences, Inc. (GILD) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs VF Corp — how do they compare? Gilead Sciences, Inc. trades at $135.55 (market cap $163.51B), while VF Corp trades at $17.27 (market cap $6.76B). The key difference: Gilead Sciences, Inc. is far larger — about 24.2× VF Corp's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | VFC | |
|---|---|---|
Market Cap | $163.51B | $6.76B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $21.55 |
52-Week Low | $108.22 | $11.66 |
Enterprise Value | $178.05B | $10.91B |
Dividend Yield | 2.49% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
VFC trades at $17.31, up 3.84% today, with a bullish technical signal and recent earnings beats in Q3 and Q4 2025. The company shows improving cash flow trends for 2026 and reduced debt-to-asset ratio to 42.42% in 2025. Revenue declined to $9.50B in 2025, but net income margin is projected to turn positive at 2.65% in 2026. Analyst consensus price target is $19.33, with 43.1% buy ratings.
Outlook suggests potential upside from current levels amid turnaround efforts, but risks include volatile earnings, high debt, and weak consumer sentiment. Investment opportunity hinges on execution of brand improvements and debt reduction, with near-term support at $17.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
